Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 676 press releases before 2019
-
AstraZeneca and Korea Health Industry Development Institute to establish oncology research programme
-
US FDA approves Bydureon® Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes
-
US FDA approves orphan drug MYALEPT™ (metreleptin for injection)
-
AstraZeneca scientists to work alongside researchers at Cancer Research UK Cambridge Institute
-
AstraZeneca PLC fourth quarter and full year results 2013
-
AstraZeneca completes the acquisition of Bristol-Myers Squibb share of global diabetes alliance
-
AstraZeneca and Shanghai Institutes of Biological Sciences announce research collaboration
-
XIGDUO™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetes
-
AstraZeneca provides update at JP Morgan Healthcare Conference on progress to achieve scientific leadership and return to growth
-
US FDA approves FARXIGA™ (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director Global Media Relations (Oncology)
+44 (0)1223 344 800
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Fiona Cookson
Director Global Media Relations (Covid-19)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
